Entyvio Side Effects
Generic name: vedolizumab
Note: This document contains side effect information about vedolizumab. Some of the dosage forms listed on this page may not apply to the brand name Entyvio.
Summary
Common side effects of Entyvio include: nasopharyngitis. Other side effects include: upper respiratory tract infection and fatigue. See below for a comprehensive list of adverse effects.
For the Consumer
Applies to vedolizumab: intravenous powder for solution
Side effects requiring immediate medical attention
Along with its needed effects, vedolizumab (the active ingredient contained in Entyvio) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking vedolizumab:
More common
- Body aches or pain
- chills
- difficulty with breathing
- ear congestion
- fever
- headache
- loss of voice
- nasal congestion
- runny nose
- sneezing
- sore throat
- unusual tiredness or weakness
Less common
- Back pain
- chest tightness
- flushing
- nausea and vomiting
- weakness
Rare
- Cough
- difficulty with swallowing
- dizziness
- fast heartbeat
- hives, itching, or skin rash
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- tightness in the chest
Incidence not known
- Abdominal or stomach pain
- blurred vision
- clay-colored stools
- confusion
- convulsions
- dark urine
- drowsiness
- headache
- loss of appetite
- lower back or side pain
- painful or difficult urination
- unpleasant breath odor
- vomiting of blood
- yellow eyes or skin
Side effects not requiring immediate medical attention
Some side effects of vedolizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Difficulty with moving
- muscle pain or stiffness
- pain in the joints
For Healthcare Professionals
Applies to vedolizumab: intravenous powder for injection
General
The most common adverse reactions were nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.[Ref]
Dermatologic
Common (1% to 10%): Rash, pruritus, eczema, erythema, night sweats, acne
Uncommon (0.1% to 1%): Folliculitis[Ref]
Gastrointestinal
Common (1% to 10%): Nausea, oropharyngeal pain, gastroenteritis, anal abscess, anal fissure, dyspepsia, constipation, abdominal distension, flatulence, hemorrhoids[Ref]
Genitourinary
Frequency not reported: Urinary tract infection[Ref]
Hepatic
Frequency not reported: Elevations of transaminase, elevations of bilirubin, hepatitis, ALT elevations, AST elevations[Ref]
Hypersensitivity
Common (1% to 10%): Infusion related reactions (e.g., infusion site reaction, infusion site pain, infusion site irritation)
Very rare (less than 0.01%): Anaphylactic reaction (e.g., dyspnea, bronchospasm, urticaria, flushing, rash, increased blood pressure, increased heart rate)[Ref]
Immunologic
Common (1% to 10%): Influenza
Uncommon (0.1% to 1%): Bacterial sepsis, septic shock
Frequency not reported: Sepsis, tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, cytomegaloviral colitis[Ref]
Musculoskeletal
Very common (10% or more): Arthralgia (12%)
Common (1% to 10%): Back pain, pain in extremities[Ref]
Nervous system
Very common (10% or more): Headache (12%)
Common (1% to 10%): Paresthesia[Ref]
Oncologic
Rare (less than 0.1%): Transitional cell carcinoma, carcinoid tumor of the appendix
Frequency not reported: B-cell lymphoma, breast cancer, colon cancer, malignant hepatic neoplasm, malignant lung neoplasm, malignant melanoma, lung cancer of primary neuroendocrine carcinoma, renal cancer, squamous cell carcinoma[Ref]
Other
Common (1% to 10%): Pyrexia, fatigue[Ref]
Respiratory
Very common (10% or more): Nasopharyngitis (13%)
Common (1% to 10%): Upper respiratory tract infection, cough, bronchitis, influenza, sinusitis
Very rare (less than 0.01%): Pneumonia[Ref]
Local
Uncommon (0.1% to 1%): Infusion site reaction (e.g., infusion site pain, infusion site irritation), infusion related reaction, chills, feeling cold[Ref]
Cardiovascular
Common (1% to 10%): Hypertension[Ref]
Frequently asked questions
- How long does it take Entyvio to start working?
- Can I drink alcohol while taking Entyvio?
- Does Entyvio cause weight gain?
- Can Entyvio cause hair loss?
- Does Entyvio cause joint pain?
- Does Entyvio increase the risk of cancer?
- Will I lose weight with Entyvio?
- Entyvio and the COVID vaccine, what should I know?
- How long does an Entyvio infusion take?
- Is Entyvio used to treat ulcerative colitis?
- Is Entyvio used to treat Crohn’s disease?
- How is Entyvio administered?
- Is Entyvio an immunosuppressant or a biologic?
- How much does Entyvio cost per month?
- Can I take antibiotics while on Entyvio?
More about Entyvio (vedolizumab)
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (117)
- Patient tips
- Drug images
- Compare alternatives
- Pricing & coupons
- En español
- Drug class: selective immunosuppressants
- FDA approval history
Patient resources
Professional resources
Related treatment guides
References
1. "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America (2014):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.